Abstract：
BACKGROUND: Recent studies have suggested that serum autotaxin (ATX) may be a promising diagnostic biomarker in differentiating between Graves\' disease (GD) and thyroiditis, as well as serving as a monitoring biomarker for GD. This study will evaluate the use of serum ATX as a diagnostic biomarker in these conditions.
METHODS: In this prospective interventional study, blood samples were collected from the patients who met both inclusion and exclusion criteria, and serum ATX levels were measured by using the MyBioSource human Autotaxin ELISA kit.
RESULTS: A total of 32 patients were enrolled, of which 18.8% were newly diagnosed with GD, 21.9% were thyroiditis, and 59.3% were on treatment for GD. Serum autotaxin antigen was significantly higher in GD patients than in thyroiditis (603.3217 ± 444.24 v/s 214.74 ± 55.91, P = <.005). Serum ATX measurement successfully discriminated GD patients from thyroiditis (AUC = 0.952, 95%CI: 0.00-1.00) with an optimal cutoff value of ≥257.20 ng/L (sensitivity = 100 and specificity = 81.71). Monitoring the efficacy of serum ATX was analyzed and showed a significant difference.
CONCLUSIONS: The serum ATX was higher in subjects with GD as compared to thyroiditis, and ATX levels were found to be decreased during the treatment period. In conclusion, serum ATX can be used as a diagnostic and monitoring biomarker in GD.
METHODS: In this prospective interventional study, blood samples were collected from the patients who met both inclusion and exclusion criteria, and serum ATX levels were measured by using the MyBioSource human Autotaxin ELISA kit.
RESULTS: A total of 32 patients were enrolled, of which 18.8% were newly diagnosed with GD, 21.9% were thyroiditis, and 59.3% were on treatment for GD. Serum autotaxin antigen was significantly higher in GD patients than in thyroiditis (603.3217 ± 444.24 v/s 214.74 ± 55.91, P = <.005). Serum ATX measurement successfully discriminated GD patients from thyroiditis (AUC = 0.952, 95%CI: 0.00-1.00) with an optimal cutoff value of ≥257.20 ng/L (sensitivity = 100 and specificity = 81.71). Monitoring the efficacy of serum ATX was analyzed and showed a significant difference.
CONCLUSIONS: The serum ATX was higher in subjects with GD as compared to thyroiditis, and ATX levels were found to be decreased during the treatment period. In conclusion, serum ATX can be used as a diagnostic and monitoring biomarker in GD.
摘要：
背景：最近的研究表明，血清自分泌运动因子（ATX）可能是区分Graves病（GD）和甲状腺炎的一个有前景的诊断生物标志物，以及作为GD的监测生物标志物。这项研究将评估血清ATX作为这些疾病的诊断生物标志物的用途。
方法：在这项前瞻性干预研究中，从符合纳入和排除标准的患者中收集血液样本，和血清ATX水平通过使用MyBioSource人AutotaxinELISA试剂盒测量。
结果：共纳入32例患者，其中18.8%新诊断为GD，21.9％为甲状腺炎，59.3%接受GD治疗。GD患者血清自分泌运动因子抗原显著高于甲状腺炎患者(603.3217±444.24v/s214.74±55.91,P=<.005)。血清ATX测量成功地将GD患者与甲状腺炎（AUC=0.952，95CI：0.00-1.00）区分开，最佳临界值≥257.20ng/L（敏感性=100，特异性=81.71）。监测血清ATX的疗效进行了分析，并显示了显着差异。
结论：GD患者的血清ATX高于甲状腺炎，发现ATX水平在治疗期间降低。总之,血清ATX可作为诊断和监测GD的生物标志物。
方法：在这项前瞻性干预研究中，从符合纳入和排除标准的患者中收集血液样本，和血清ATX水平通过使用MyBioSource人AutotaxinELISA试剂盒测量。
结果：共纳入32例患者，其中18.8%新诊断为GD，21.9％为甲状腺炎，59.3%接受GD治疗。GD患者血清自分泌运动因子抗原显著高于甲状腺炎患者(603.3217±444.24v/s214.74±55.91,P=<.005)。血清ATX测量成功地将GD患者与甲状腺炎（AUC=0.952，95CI：0.00-1.00）区分开，最佳临界值≥257.20ng/L（敏感性=100，特异性=81.71）。监测血清ATX的疗效进行了分析，并显示了显着差异。
结论：GD患者的血清ATX高于甲状腺炎，发现ATX水平在治疗期间降低。总之,血清ATX可作为诊断和监测GD的生物标志物。
